Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Statement to the U.S. International Trade…
Ag Value Chain Letter to President Biden on…
As organizations representing America’s highly innovative and competitive food and agricultural value chain, we write to express our thanks for USTR’s announcement that it will begin technical consultations with Mexico concerning its action to ban…
BIO Comments to CMS on the Proposed Rule Dealing…
BIO’s comments on specific aspects of CMS’s Proposed Rule on Medicaid drug pricing are presented below.
All Letters, Testimony & Comments
  • Show All
Search
March 9, 2023
As organizations representing America’s highly innovative and competitive food and agricultural value chain, we write to express our thanks for USTR’s announcement that it will begin technical consultations with Mexico concerning its action to ban…
February 13, 2023
BIO’s comments on specific aspects of CMS’s Proposed Rule on Medicaid drug pricing are presented below.
February 5, 2023
ABA has submitted comments to the Office of Science & Technology Policy on how regulations underpinning the Coordinated Framework for the Regulation of Biotechnology can better facilitate the use of biotechnology to stimulate the economy…
February 5, 2023
BIO has submitted comments to the Office of Science & Technology Policy on how regulations underpinning the Coordinated Framework for the Regulation of Biotechnology can better facilitate the use of biotechnology to stimulate the economy…
January 23, 2023
BIO's response to the Office of Science & Technology Policy's Request for Information concerning the National Biotechnology & Biomanufacturing Initiative
January 3, 2023
On Tuesday, January 3rd, BIO submitted comments in response to the Food and Drug Administration’s (FDA) recent draft guidance containing recommendations for sponsors on monitoring growth and evaluating pubertal development in clinical trials which…
December 13, 2022
On Tuesday, December 13th, BIO submitted comments in response to a recent FDA discussion paper for stakeholders on distributed manufacturing (DM) and point-of-care (POC) manufacturing. In the comments submitted, BIO commended the FDA on its…